Zamboulis 1996.

Methods	4‐week washout; 2‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 95‐114 mm Hg at end of placebo run‐in; 4‐week double‐blind treatment
Participants	Fosinopril 20 mg: n=12(8 males,4 females); mean age=51 years; baseline seated SBP=150.8(15.9) mm Hg, DBP=108.8(4.7) mm Hg; baseline HR=76.9(5.3) bpm; Placebo: n=11(7 males,4 females); mean age=45 years; baseline seated SBP=143.0(20.0) mm Hg, DBP=95.5(12.6) mm Hg; baseline HR=79.0(9.8) bpm
Interventions	Fosinopril 20 mg once daily; Placebo
Outcomes	Sitting SBP/DBP using mercury sphygmomanometer; WDAE
Notes	BP change and SD of change not reported, endpoint BP and SD reported; imputed endpoint SD for SD of change; time of BP measurement (peak and/or trough) not reported; BP data from Table 1, p. 254; Jadad score=3; funding source= Bristol‐Myers Squibb
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear

BP=blood pressure, DBP=diastolic blood pressure; SBP=systolic blood pressure; SD=standard deviation; WDAE=withdrawal due to adverse effects; bpm=beats per minute